Complete Reversal of ABCG2-Depending Atypical Multidrug Resistance by RNA Interference in Human Carcinoma Cells

2006 ◽  
Vol 16 (3) ◽  
pp. 263-274 ◽  
Author(s):  
Axel Priebsch ◽  
Franziska Rompe ◽  
Holger Tönnies ◽  
Petra Kowalski ◽  
Pawel Surowiak ◽  
...  
2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Dan Xu ◽  
Da Wei Li ◽  
Jin Xie ◽  
Xin Wei Chen

This study aimed at clarifying the mechanism and role of survivin in hypoxia-induced multidrug resistance (MDR) of laryngeal carcinoma cells. Human laryngeal cancer cells were incubated under hypoxia or normoxia. The expression of survivin was silenced by performing RNA interference. Additionally, by Western blot and real-time quantitative RT-PCR, survivin expression was detected. The sensitivity of human laryngeal carcinoma cells to multiple drugs was measured by CCK-8 assay. Meanwhile, the apoptosis of cells induced by cisplatin or paclitaxel was assessed by Annexin-V/propidium iodide staining analysis. Under hypoxic conditions, the upregulation of survivin was abolished by RNA interference. Then, CCK-8 analysis demonstrated that the sensitivity to multiple agents of laryngeal carcinoma cells could be increased by inhibiting survivin expression (P<0.05). Moreover, Annexin-V/propidium iodide staining analysis revealed that decreased expression of survivin could evidently increase the apoptosis rate of laryngeal carcinoma cells that were induced by cisplatin or paclitaxel evidently (P<0.05). Our data suggests that hypoxia-elicited survivin may exert a pivotal role in regulating hypoxia-induced MDR of laryngeal cancer cells by preventing the apoptosis of cells induced by chemotherapeutic drug. Thus, blocking survivin expression in human laryngeal carcinoma cells may provide an avenue for gene therapy.


2001 ◽  
Vol 92 (8) ◽  
pp. 886-895 ◽  
Author(s):  
Shunji Aoki ◽  
Zhe-Sheng Chen ◽  
Kimihiko Higasiyama ◽  
I Setiawan ◽  
Shin-ichi Akiyama ◽  
...  

Author(s):  
Douglass F. Taber

The complex polycyclic structure of N-methylwelwitindolinone D isonitrile 3 was assigned in 1999. The welwitinines show an intriguing range of biological activity, including reversal of P-glycoprotein-mediated multidrug resistance in human carcinoma cells. Viresh H. Rawal of the University of Chicago described (J. Am. Chem. Soc. 2011, 133, 5798) the first synthesis of 3, using as a key step the Pd-catalyzed cyclization of 1 to 2. The ketone 1 was assembled by the convergent coupling of 7 with 11. The indole 7 was readily available by Batcho-Leimgruber cyclization of commercial 4 to 5. The expected 3-acylation followed by N -methylation delivered the stable ketone 6. The unstable 7 was prepared as needed. The anisole 8 was the starting material for the preparation of the alicyclic diene 11. Although this synthesis was carried out in the racemic series, enantiomerically enriched 9 could be prepared by Shi epoxidation of the β,γ-unsaturated ketone from Birch reduction The alcohol 7 was not stable to silica gel chromatography. The mixture of 11 with the crude alcohol 7 was therefore activated by the addition of TMSOTf, then added via cannula to aqueous HClO4 in THF to deliver the coupled product 1 as a single diastereomer. The remarkable cyclization of 1 to 2 required extensive screening. Eventually it was found that a combination of ( t -Bu)3 P with Pd(OAc)2 as the Pd source worked well. This concise convergent synthetic strategy makes the welwitinine core 2 available in gram quantities. There were two problems to be solved in the conversion of 2 to 3. The first was the installation of the oxy bridge. Indoles are notoriously sensitive to overoxidation. Nevertheless, addition of an acetone solution of dimethyl dioxirane to the bromo ketone 12 over 24 hours gave clean conversion to 13. The remaining challenge was the conversion of the aldehyde of 13 to the isonitrile. Kim had described the inversion of an oxime to the isothiocyanate. Optimization of this protocol led to the thiourea 14 as the best for this transformation. Mild desulfurization then delivered N -methylwelwitindolinone D isonitrile 3.


2016 ◽  
Vol 11 (03) ◽  
Author(s):  
L Berti ◽  
B Rädle ◽  
HU Häring ◽  
M Hrab((ebrevis)) de Angelis ◽  
H Staiger

Tumor Biology ◽  
2011 ◽  
Vol 32 (6) ◽  
pp. 1217-1224 ◽  
Author(s):  
Yuncheng Li ◽  
Sulin Zhang ◽  
Zhengang Tang ◽  
Jian Chen ◽  
Weijia Kong

2015 ◽  
Vol 55 (1) ◽  
pp. 31-40 ◽  
Author(s):  
Micaela Cunha ◽  
Etienne Testa ◽  
Olga V. Komova ◽  
Elena A. Nasonova ◽  
Larisa A. Mel’nikova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document